Loading…
Loading…
HSPT (Horizon Space Acquisition II Corp.) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
HSPT does not currently pay a dividend.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for HSPT and 80,000+ other tickers.
See exactly how HSPT's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for HSPT and 80,000+ other tickers.
Horizon Space Acquisition II Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities. The company was incorporated in 2023 and is based in New York, New York.
Post-combination company, SL Science Holding Limited, to commence trading on the Nasdaq Stock Market under the ticker symbol "SLBT"Transaction provides strategic capital to advance proprietary Gamma delta T cell-based "off-the-shelf" cellular therapies for solid tumor indications, including pancreatic and brain cancersLeadership team bolstered by seasoned executives and highly experienced independent directors to drive the next phase of clinical and commercial growth TAIPEI, Taiwan, June 12, 2026 (GLOBE NEWSWIRE) -- SL BIO Ltd.
New York, NY, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Horizon Space Acquisition II Corp. (the “Company” or “HSPT”) (NASDAQ: HSPT) today clarified the redemption process for (i) the extraordinary general meeting for its proposed business combination (the “Business Combination”) with SL BIO Ltd. (“SL Bio”), which will be held on February 12, 2026 (the “Business Combination Meeting”), and (ii) the extraordinary general meeting for its proposed amendments to HSPT's current amended and restated memorandum and articles of association, and the Investment Management Trust Agreement (collectively, the “Extension Proposals”), to extend the deadline to complete its initial business combination, which will be held on February 13, 2026 (the “Extension Meeting”).
New York, NY, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Horizon Space Acquisition II Corp. (the “Company” or “HSPT”) (NASDAQ: HSPT) today announced that it postponed the extraordinary general meeting (the “Extraordinary Meeting”) originally scheduled at 9:00 a.m. Eastern Time, on February 3, 2026, to 9:00 a.m. Eastern Time, on February 12, 2026 (the “Postponement”) to allow the Company additional time to engage with its shareholders.
Dealmaking persists as creditors, buyers, and investors wrestle with debt, delays, and mega-merger ambitions.
NEW YORK, NY / ACCESS Newswire / May 12, 2025 / Horizon Space Acquisition II Corp. ("HSPT") (Nasdaq:HSPT), a publicly traded special purpose acquisition company, and SL Bio Ltd. ("SL Bio"), a clinical-stage biomedical company specialized in developing groundbreaking cellular and gene therapies for skin care and cancer recovery, today announced that they have entered into a definitive business combination agreement (the "Business Combination Agreement").